FDA Warns Novo On Drug Contamination Measures

Law360, New York (February 5, 2013, 2:48 PM EST) -- The U.S. Food and Drug Administration revealed Tuesday that it had sent a warning letter to Danish drugmaker Novo Nordisk A/S, accusing it of failing to properly implement anti-contamination measures at one of its drug manufacturing plants.

According to the letter, dated Dec. 12 but made publicly available Tuesday, a March 2012 inspection of Novo's Bagsvaerd, Denmark-based plant had revealed "significant" violations of the FDA's current good manufacturing practice, including a failure to properly follow procedures designed to prevent microbiological contamination of drug products, and a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.